 |
306 Products |  |
1129 Diseases | | 306 Products |
|
4023 Trials |  |
219432 News |  |
| «12...1415161718192021222324...26722673» |
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: U2SURP increases CREB3L2 RNA stability and RIOK1 transcription to enhance lenvatinib resistance in hepatocellular carcinoma cells. (Pubmed Central) - Apr 19, 2026
U2SURP reduces the sensitivity of HCC cells to LEV by stabilizing CREB3L2 and activating RIOK1. The U2SURP/CREB3L2/RIOK1 axis may serve as a potential intervention target to enhance the efficacy of LEV in HCC.
- | Keytruda (pembrolizumab) / Merck (MSD), Retevmo (selpercatinib) / Eli Lilly, pemetrexed / Generic mfg.
Journal: Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. (Pubmed Central) - Apr 19, 2026
The U2SURP/CREB3L2/RIOK1 axis may serve as a potential intervention target to enhance the efficacy of LEV in HCC. The results of Study LIBRETTO-431, an ex-US multiregional, open-label, randomized, active-controlled trial of selpercatinib versus platinum-based and pemetrexed chemotherapy with or without pembrolizumab in patients with treatment-na
- | cisplatin / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair. (Pubmed Central) - Apr 19, 2026
Notably, compound Ola-604 demonstrated higher tumor growth inhibitory efficacy than cisplatin, olaparib, and their physical mixture in SKOV3 mice xenograft models, while exhibiting lower toxicity. Overall, the TDC entity sets a new benchmark for precision therapy in ovarian cancer.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker: Protein Kinase D1 Translocates PARP1 to the Membrane and Is Associated With Increased Sensitivity to Cell Viability Inhibition by PARP1 Inhibitor Olaparib. (Pubmed Central) - Apr 19, 2026
Co-targeting PrKD1 using small molecular inhibitors may enhance olaparib efficacy at lower doses and improve PARPi tolerability and therapeutic index. The demonstration of PARP1 at the membrane is novel, introducing the possibility of targeting membranous PARP1 for theranostic applications.
- || Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Observational data, Retrospective data, Journal, Adverse events: Effectiveness of oral antivirals in reducing adverse outcomes in asthmatic patients with non-severe COVID-19: A multi-institutional retrospective cohort study. (Pubmed Central) - Apr 19, 2026
Significantly risk reduction was also observed in subgroups including both sexes, different ages, those with hypertension, dyslipidemia, diabetes mellitus, those receiving NMV-r, and those who had received less than 1 dose and more than 3 doses of vaccine. Our findings suggest oral antivirals, particularly NMV-r, reduce adverse outcomes in asthmatic patients with non-severe COVID-19.
- | vancomycin / Generic mfg., Dificid (fidaxomicin) / Merck (MSD), Astellas
Clinical, Observational data, Retrospective data, Journal, HEOR: Comparative effectiveness of vancomycin and fidaxomicin in the treatment of Clostridioides difficile-associated diarrhea: A single-center experience in Taiwan. (Pubmed Central) - Apr 19, 2026
Fidaxomicin demonstrated superior clinical effectiveness to vancomycin, particularly among older adults and patients with multiple comorbidities. These findings support prioritizing fidaxomicin for high-risk patients and considering fecal microbiota transplantation in refractory cases.
- | Journal: Clinical and Microbiological Insights Into Invasive Fusariosis Following Allogeneic Hematopoietic Stem Cell Transplantation: A 15-Year Single-Center Analysis. (Pubmed Central) - Apr 18, 2026
Despite the small sample size, outcomes were not clearly associated with MIC values. Early L-AMB plus VRCZ and neutrophil recovery may be associated with improved survival.
- | Cubicin (daptomycin) / Merck (MSD)
Journal: Daptomycin failure in the treatment of Enterococcus faecium bacteremia: microbiological insights and the importance of dual therapy including beta-lactam. (Pubmed Central) - Apr 18, 2026
Early L-AMB plus VRCZ and neutrophil recovery may be associated with improved survival. No abstract available
- | Journal, PARP Biomarker: Identification of novel drug-specific PARP inhibitor resistance mechanisms in ovarian cancer-implications for clinical practice. (Pubmed Central) - Apr 18, 2026
Treatment-induced BCRP/ABCG2 induction is a novel clinically relevant niraparib resistance biomarker. Routine inclusion of paclitaxel in first-line chemotherapy regimens may promote efflux transporter-mediated resistance, compromising response to PARPi maintenance treatment.
- | MK-2206 / Merck (MSD), Iclusig (ponatinib) / Takeda
Journal: Ponatinib confers adult human cardiomyocyte toxicity via inhibition of AKT signaling. (Pubmed Central) - Apr 18, 2026
We reveal suppression of AKT, but not ERK, phosphorylation upon ponatinib treatment. Treatment of hPCMs with AKT inhibitor MK-2206 phenocopied ponatinib, while restoration of AKT signaling with UCL-TRO-1938 or insulin partially rescued hPCMs from cell death, suggesting a potential protective effect.
- || Retrospective data, Review, Journal, Adverse events, Checkpoint inhibition: Incidence and Comparative Risk of Hematological Adverse Events Across Different Immune Checkpoint Inhibitors: A Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Apr 18, 2026
For thrombocytopenia, ipilimumab ranked highest, followed by sintilimab and nivolumab, while toripalimab showed the least favorable ranking...However, given the star-shaped network structure, reliance on indirect comparisons, and observed heterogeneity, the results should be interpreted cautiously. While not definitive, the analysis may still offer preliminary insights to inform treatment selection, particularly for patients with baseline hematological vulnerabilities or those receiving concurrent myelosuppressive therapies, and may help guide the development of risk-stratified monitoring strategies in clinical practice.
- | Review, Journal: Sodium-Glucose Cotransporter-2 Inhibitors Across the Glycemic Spectrum: Cardiovascular and Renal Outcomes With Mechanistic Insights. (Pubmed Central) - Apr 18, 2026
Evidence gaps remain for stage 5 CKD and dialysis populations and for defining outcomes in lower-risk post-myocardial infarction cohorts. Overall, current data support SGLT2 inhibitors as foundational therapy for eligible patients with HF and/or CKD irrespective of diabetes status.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Cutaneous Groin Metastasis as a Rare Presentation of Advanced Urothelial Carcinoma of the Bladder. (Pubmed Central) - Apr 18, 2026
Before hospitalization, he had been treated with chemotherapy, radical cystectomy with ileal conduit, and pembrolizumab...The patient ultimately died of disease progression. This case highlights the importance of recognizing atypical metastatic presentations, managing immunotherapy-related toxicities, and incorporating early palliative care discussions.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Review, Journal: A Narrative Review of the Therapeutic Effectiveness of Lenvatinib in Comparison With Immunotherapy for the Treatment of Non-Viral Advanced Hepatocellular Carcinoma. (Pubmed Central) - Apr 18, 2026
Evidence suggests superior survival outcomes compared with ICIs. Etiology-specific responses highlight the need for stratified therapeutic approaches and consideration of lenvatinib-based combination therapies.
- | Retrospective data, Review, Journal, Checkpoint inhibition: Efficacy of first-line immune checkpoint inhibitors in advanced non-small-cell lung cancer with or without brain metastases: a systematic review and network meta-analysis. (Pubmed Central) - Apr 18, 2026
These findings, currently limited by low-certainty indirect evidence, warrant validation in adequately powered, head-to-head trials. https://www.crd.york.ac.uk/prospero/, identifier CRD420251236228.
- | Review, Journal, IO biomarker: Non-small cell lung cancer research: advances and persistent challenges. (Pubmed Central) - Apr 18, 2026
Next-generation tyrosine kinase inhibitors (TKIs), including lorlatinib, tepotinib, and glecirasib, have shown improved outcomes for patients with oncogene-driven NSCLC...Future efforts must prioritize overcoming resistance through combination strategies and ADCs, validating biomarkers using AI and ctDNA, streamlining CGP implementation, and addressing the unique needs of special populations. Bridging these biological and systemic challenges is essential for improving survival outcomes and ensuring equitable benefits for all NSCLC patients.
- | Invanz (ertapenem) / Merck (MSD), gentamicin sulfate / Generic mfg.
Biomarker, Journal, Next-generation sequencing: Antimicrobial use on Campylobacter revealed by next-generation sequencing in patients with common variable immunodeficiency. (Pubmed Central) - Apr 18, 2026
Similar to patient #1, three of the isolates from 2023 had an A1464G 16S rRNA mutation and were gentamicin resistant. Retrospective analyses of antimicrobial use for both patients highlighted an association between antimicrobial selection pressure and the emergence of resistance markers, suggesting in vivo selection.
- ||| P3 data, Journal: DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer. (Pubmed Central) - Apr 18, 2026
P2, P3
DESTINY-Gastric05 (NCT06731478) is a global, multicenter, open-label, randomized, phase III trial to evaluate the efficacy and safety of first-line T-DXd 5.4 mg/kg plus 5-fluorouracil or capecitabine and pembrolizumab versus platinum-based chemotherapy with trastuzumab and pembrolizumab in patients with unresectable, locally advanced or metastatic, centrally confirmed HER2-positive (immunohistochemistry 3+ or immunohistochemistry 2+/in situ hybridization positive) gastric or GEJ cancer with a PD-L1 CPS ?1. An exploratory cohort is to evaluate T-DXd plus 5-fluorouracil or capecitabine in patients with PD-L1 CPS <1.
- | Review, Journal, PD(L)-1 Biomarker, IO biomarker: Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025. (Pubmed Central) - Apr 18, 2026
Novel agents like saruparib and pasritamig showed promise...The 2025 evidence establishes multiple new standards of care across GU cancers, emphasizing biomarker-driven strategies, immunotherapy integration, novel resistance mechanisms, and treatment optimization. This synthesis provides an evidence-based framework for updating guidelines and highlights the move toward more personalized management, while noting persistent challenges and future research needs.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: Complete response to pembrolizumab in a paediatric patient with Lynch syndrome-associated colorectal cancer: a case report and review of immunotherapy-related bowel obstruction. (Pubmed Central) - Apr 18, 2026
After surgery, there was no pathological evidence of residual adenocarcinoma. This case demonstrates the potential of pembrolizumab in paediatric CRC, highlighting the importance of molecular-guided rather than age-restricted therapy selection.
- | Journal, Checkpoint inhibition: Effectiveness comparison of pembrolizumab versus other immune checkpoint inhibitors in neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma. (Pubmed Central) - Apr 18, 2026
Domestic and imported immune drugs demonstrated comparable long-term survival and safety in ESCC patients receiving nICT. Although imported agents may offer a modest advantage in pathological response, both categories remain effective options for clinical use.
- | Journal, Real-world evidence: UK Antimicrobial Registry: Virtual Registry-an innovative surveillance approach for monitoring the real-world use and effectiveness of newly licensed antimicrobials in Scotland. (Pubmed Central) - Apr 18, 2026
UKAR:V shows that linked electronic data can support real-world RLA surveillance. With appropriate data linkage, this model offers a scalable, low-burden approach to monitoring utilization/outcomes providing a sustainable foundation for stewardship/policy and assessment of innovative reimbursement models.
- | Review, Journal, PD(L)-1 Biomarker: Nanoparticle-mediated mRNA delivery for cancer, autoimmunity, and genetic diseases: a rapid review. (Pubmed Central) - Apr 18, 2026
Clinically, individualized mRNA neoantigen therapy (mRNA-4157/V940) combined with pembrolizumab reduced recurrence risk by approximately 49% in high-risk melanoma in the KEYNOTE-942 phase 2b trial, supporting phase 3 development...Advances in biodegradable ionisable lipids, organ-selective LNPs, and lyophilised or solid formulations are being developed to address persistent delivery and manufacturing constraints. As the field matures, regulatory and policy frameworks will need to align with therapeutic endpoints and support long-term safety monitoring.
- | Journal, BRCA Biomarker, PARP Biomarker: Matching-Adjusted Indirect Comparisons of PARP Inhibitor Combinations in Metastatic Castration-Resistant Prostate Cancer Across Key Populations. (Pubmed Central) - Apr 18, 2026
MAICs showed improved clinical benefit with TALA+ENZA versus OLAP+AAP and NIRA+AAP across multiple mCRPC populations and endpoints. Despite limitations of indirect comparisons, findings support TALA+ENZA as a first-line treatment option for mCRPC.
- | Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Observational data, Journal: Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study. (Pubmed Central) - Apr 18, 2026
The effectiveness of molnupiravir in reducing hospitalization and death may be insufficient in previously immune COVID-19 patients. Additionally, molnupiravir may reduce day-28 serum SARS-CoV-2 antibody level.
- | darunavir/ritonavir / Generic mfg., raltegravir / Generic mfg.
Biomarker, Journal: Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART. (Pubmed Central) - Apr 18, 2026
Additionally, molnupiravir may reduce day-28 serum SARS-CoV-2 antibody level. Plasma biomarkers of brain health improved following ART initiation, associated predominantly with improvements in CD4 count and partly with treatment arm.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The KRT15 and KRT81 complex promotes lenvatinib resistance in thyroid cancer by upregulating DGKB mediated lipid metabolism. (Pubmed Central) - Apr 18, 2026
This study illustrates a novel mechanism of cytoskeletal proteins involvement in metabolic adaptation of drug-resistant thyroid cancer cells. The KRT15-KRT81-DGKB pathway is a promising therapeutic target, particularly in combination with lenvatinib, for refractory thyroid cancer patients.
- | Journal: An integrated restricted mean survival time-based evaluation of efficacy, toxicity, and cost in first-line immunotherapy regimens for metastatic renal cell carcinoma. (Pubmed Central) - Apr 18, 2026
The KRT15-KRT81-DGKB pathway is a promising therapeutic target, particularly in combination with lenvatinib, for refractory thyroid cancer patients. Integrated RMST-based analyses reveal clinically relevant trade-offs across regimens and distinct multidimensional profiles that may inform comparative treatment interpretation.
- | Keytruda (pembrolizumab) / Merck (MSD), Provenge (sipuleucel-T) / Bausch Health
Review, Journal: Novel immunotherapies for prostate cancer. (Pubmed Central) - Apr 18, 2026
Aside from the infrequent use of pembrolizumab immune checkpoint blockade in rare molecularly-selected patients, no further immune approaches have achieved regulatory approval...Nevertheless, recent advances in drug design and cellular engineering have reinvigorated interest in novel immunotherapeutic approaches in prostate cancer. This review provides an overview of the current landscape of novel immunotherapy clinical development for prostate cancer, with a focus on chimeric antigen receptor (CAR) T cells, T cell engagers, monoclonal antibodies, and cancer vaccine approaches that have produced promising early phase clinical data.
- | Journal, HEOR, Real-world evidence: CLO26-112: Durvalumab Versus Pembrolizumab With Gemcitabine and Cisplatin in First-Line Treatment of Advanced Biliary Tract Cancer: A Real-World Comparative Effectiveness Analysis. (Pubmed Central) - Apr 18, 2026
This review provides an overview of the current landscape of novel immunotherapy clinical development for prostate cancer, with a focus on chimeric antigen receptor (CAR) T cells, T cell engagers, monoclonal antibodies, and cancer vaccine approaches that have produced promising early phase clinical data. No abstract available
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: CRE26-067: Treatment Response to Lenvatinib in Metastatic Adenoid Cystic Triple Negative Breast Cancer: A Case Report. (Pubmed Central) - Apr 18, 2026
No abstract available No abstract available
- | Journal: COVID-19 State of Emergency and Biological Therapy Persistence for Ulcerative Colitis: An Interrupted Time Series Study Using a Nationwide Claims Database. (Pubmed Central) - Apr 18, 2026
Biological therapy persistence for ulcerative colitis was largely maintained during the COVID-19 pandemic in Japan. These findings suggest that the pandemic was not associated with a marked change in treatment persistence in this setting.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: CRE26-050: Expanding Therapeutic Boundaries: Durable Remission of EBV-Positive NK/T-Cell Lymphoma With Pembrolizumab in the Setting of Renal Dysfunction. (Pubmed Central) - Apr 18, 2026
These findings suggest that the pandemic was not associated with a marked change in treatment persistence in this setting. No abstract available
- | idebenone / Generic mfg., Koselugo (selumetinib) / AstraZeneca
Journal: Dissecting the impact of SHC-1 inhibitors in enhancing the plasma membrane abundance of the CFTR channel across epithelial cell models. (Pubmed Central) - Apr 18, 2026
No significant effects were observed in 16HBE or Caco-2?cells. These findings suggest CFBE cells may not fully recapitulate endogenous CFTR trafficking and raise the possibility that selective SHC-1/pY512-CFTR inhibitors may modulate CFTR trafficking in COPD and other CFTR-related diseases.
- | Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / BMS
Review, Journal: Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions. (Pubmed Central) - Apr 18, 2026
These findings suggest CFBE cells may not fully recapitulate endogenous CFTR trafficking and raise the possibility that selective SHC-1/pY512-CFTR inhibitors may modulate CFTR trafficking in COPD and other CFTR-related diseases. Current evidence strongly supports incorporating NAST into standard clinical practice for resectable clinical stage III and IV melanoma, promising substantial improvements in patient outcomes with acceptable safety profiles.
- | Keytruda (pembrolizumab) / Merck (MSD), Lynparza (olaparib) / Merck (MSD), AstraZeneca
Clinical data, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker: Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. (Pubmed Central) - Apr 18, 2026
GGT prevalence has increased at RPCCC and informed treatment decisions. Universal point-of-care testing is being implemented with the goal of completing testing for all patients with PDAC seen at RPCCC.
- | Keytruda (pembrolizumab) / Merck (MSD)
Biomarker, Review, Journal, PD(L)-1 Biomarker: Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. (Pubmed Central) - Apr 18, 2026
The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease outcomes...Biomarker strategies including tumor infiltrating lymphocytes, immune signatures, and circulating tumor DNA are being explored to identify patients at a high risk of relapse and to predict treatment response. In this article, we review recent advances in the management of stage II to III TNBC, highlight emerging investigational therapies and combinations, and explore novel biomarker strategies aimed at personalizing the care for patients with stage II to III TNBC.
- |||||| ifinatamab deruxtecan (DS-7300) / Daiichi Sankyo, Merck (MSD)
New trial: Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov) - Apr 18, 2026
P=N/A, N=0, Temporarily Not Available, Sponsor: Daiichi Sankyo
- | MOMA-313 / MOMA Therapeutics
Enrollment closed, Monotherapy, First-in-human: MOMA-313-001: Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Apr 17, 2026
P1, N=220, Active, not recruiting, Sponsor: MOMA Therapeutics
In this article, we review recent advances in the management of stage II to III TNBC, highlight emerging investigational therapies and combinations, and explore novel biomarker strategies aimed at personalizing the care for patients with stage II to III TNBC. Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change: CHANCE2201: TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC (clinicaltrials.gov) - Apr 17, 2026
P=N/A, N=1244, Completed, Sponsor: Zhongda Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed | N=474 --> 1244
- | Paxlovid (nirmatrelvir/ritonavir) / Pfizer, favipiravir / Generic mfg., Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Bio-inspired chemometric methods for simultaneous UV spectrophotometric determination of molnupiravir, nirmatrelvir, and favipiravir in pharmaceutical formulations and environmental samples. (Pubmed Central) - Apr 17, 2026
Recruiting --> Completed | N=474 --> 1244 No abstract available
- | sirolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: mTOR-driven integrin ?4-enriched extracellular vesicles from lenvatinib-resistant hepatocellular carcinoma fuel lung metastasis via fibroblast-niche formation. (Pubmed Central) - Apr 17, 2026
Moreover, inhibition of mTOR signaling using rapamycin impeded lung metastasis and restored the sensitivity to lenvatinib. These findings highlight the role of ITG?4-enriched EVs released from LR HCC cells in promoting lung metastasis and propose a potential target for combating lung metastasis and overcoming lenvatinib resistance.
- | Keytruda (pembrolizumab) / Merck (MSD)
Retrospective data, Journal, Monotherapy, PD(L)-1 Biomarker: CLO26-102: Progression-Free Survival of Pembrolizumab Monotherapy Versus Combination Therapy With Chemotherapy as First-Line Treatment in Advanced or Metastatic Non-Small-Cell Lung Cancer Without EGFR/ALK Mutations: A Systematic Review and Robust Meta-Analysis. (Pubmed Central) - Apr 17, 2026
These findings highlight the role of ITG?4-enriched EVs released from LR HCC cells in promoting lung metastasis and propose a potential target for combating lung metastasis and overcoming lenvatinib resistance. No abstract available
- | New P4 trial: Comparison of Antihistamine and Antileukotriene Add-On Therapy to Intranasal Corticosteroid in Allergic Rhinitis (clinicaltrials.gov) - Apr 16, 2026
P4, N=32, Not yet recruiting, Sponsor: Liaquat National Hospital & Medical College
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date: NeoPeSino: Pembrolizumab in Locally Advanced Sinonasal Carcinoma (clinicaltrials.gov) - Apr 16, 2026
P2, N=28, Recruiting, Sponsor: Istituti Clinici Scientifici Maugeri SpA
No abstract available Trial completion date: Nov 2026 --> Dec 2027
- | Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) / Merck (MSD)
Trial completion: GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose (clinicaltrials.gov) - Apr 16, 2026
P4, N=767, Completed, Sponsor: The University of Texas Medical Branch, Galveston
Trial completion date: Nov 2026 --> Dec 2027 Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion: Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study (clinicaltrials.gov) - Apr 16, 2026
P2, N=45, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Belsomra (suvorexant) / Merck (MSD)
Trial completion, Enrollment change: Treating Insomnia and Improving Metabolic Health in Midlife Women With Insomnia (clinicaltrials.gov) - Apr 16, 2026
P4, N=31, Completed, Sponsor: Brigham and Women's Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=61 --> 31
- | carboplatin / Generic mfg., Keytruda (pembrolizumab) / Merck (MSD), albumin-bound paclitaxel / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Durable response of anaplastic thyroid cancer to pembrolizumab combined with chemotherapy: A case report. (Pubmed Central) - Apr 16, 2026
The favorable response in this case suggests that further evaluation of this triplet regimen could be considered for anaplastic thyroid cancer, though this remains a speculative premise requiring validation. Further studies are also needed to clarify the underlying mechanisms of this combination and to identify predictive biomarkers for patient selection.
- | Remicade (infliximab) / J&J, Stelara (ustekinumab) / J&J
Journal: A Case Study and Review of the Literature on IgA Nephropathy in Crohn's Disease. (Pubmed Central) - Apr 16, 2026
Infliximab was discontinued, and a subsequent intestinal flare was successfully treated with ustekinumab. This case highlights the importance of vigilant renal monitoring in pediatric CD, particularly in patients with prior intestinal surgery or long-term biologic therapy.